06:01 AM EDT, 09/05/2025 (MT Newswires) -- BioNTech (BNTX) and China's Duality Biologics said Friday that their phase 3 trial evaluating trastuzumab pamirtecan in patients with a certain type of breast cancer met its primary endpoint in an interim analysis.

A joint statement said the study, which compared BioNTech's trastuzumab pamirtecan drug candidate with Roche's approved antibody drug-conjugate trastuzumab emtansine, reached its primary endpoint of progression-free survival in an interim analysis.

The patients involved in the study had HER2-positive unresectable or metastatic breast cancer and had previously received trastuzumab and a taxane-based chemotherapy, the companies said.

Shares of the company were up 1.5% in recent Friday premarket activity.